ARDELYX, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend

ARDELYX, INC. (ARDX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend of $0 for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-17.

Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend · last filed 2017-02-17

ARDELYX, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average expected dividend for fiscal 2016 was $0.00.
ARDELYX, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average expected dividend for fiscal 2015 was $0.00.

Period end	Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend 12 month
2016-12-31	$0.00 10-K · filed 2017-02-17
2015-12-31	$0.00 10-K · filed 2016-03-04

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Avalo Therapeutics, Inc. (AVTX)	United States	$0.842B	-9.74
Immix Biopharma, Inc. (IMMX)	United States	$0.837B	-18.44
Cryoport, Inc. (CYRX)	United States	$0.881B	-21.29
Theravance Biopharma, Inc. (TBPH)		$0.885B	16.40
Obsidian Therapeutics, Inc. (OBX)	United States	$0.829B
LEXICON PHARMACEUTICALS, INC. (LXRX)	United States	$0.823B	-17.48
RIGEL PHARMACEUTICALS INC (RIGL)	United States	$0.893B	2.25
GYRE THERAPEUTICS, INC. (GYRE)	United States	$0.818B	-24.71
Apnimed, Inc. (APMD)	United States	$0.899B
GERON CORP (GERN)	United States	$0.803B	-12.14